Novo Nordisk Archives

News and Trends 17 Aug 2018

Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M

Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the […]

August 17, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […]

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

It’s World Diabetes Day! But What is Biotech Doing to Fight the Disease?

Diabetes is now a major epidemic, with 425 million people living with the condition. Luckily, biotech is working on ways to stop it in its tracks. Not only is it Antibiotic Awareness Week, but today is World Diabetes Day. This year’s theme draws attention to diabetes in women and the right to live a healthy life. […]

November 14, 2017 - 4 minutesmins - By Alex Dale

Novo Nordisk Semaglutide GLP 1 receptor agonist type 2 diabetes Eli Lilly Trulicity dulaglutide

More News! 18 Aug 2017

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […]

August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 6 Jun 2017

French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug

Novo Nordisk has handed over its anti-cancer antibody to Innate Pharma in a new deal that could earn the diabetes specialist up to €370M in milestones. The immuno-oncology biotech Innate Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, […]

June 6, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 21 Mar 2017

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]

March 21, 2017 - 7 minutesmins - By Evelyn Warner

Interview 27 Feb 2017

Meet the Woman developing the Next Generation of Insulin

Fiasp, ultra-fast-acting insulin, could revolutionize insulin. We chatted with Liselotte Hyveled, the woman heading the team behind it. “I didn’t get into nursing school, so I went into pharmacy instead,” Liselotte Hyveled laughs. “In Denmark, we have free education, but the government limits degrees for students based on job market needs. There was a low […]

February 27, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 31 Jan 2017

Top 5 Biologicals from European Biopharma to Launch in 2017

A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University

A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […]

December 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 4 Nov 2016

Roche hits a Speed Bump on the way to a Hemophilia Cure

The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […]

November 4, 2016 - 4 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us